Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

2.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

3.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
4.

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.

Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A.

Curr Opin Rheumatol. 2012 May;24(3):290-8. doi: 10.1097/BOR.0b013e32835257c5. Review.

PMID:
22418743
5.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group.

Ann Rheum Dis. 2006 Mar;65(3):316-20. Epub 2005 Aug 11.

6.

Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.

Ren L, Li J, Luo R, Tang R, Zhu S, Wan L.

Am J Med Sci. 2013 Dec;346(6):455-61. doi: 10.1097/MAJ.0b013e3182926a23. Review.

PMID:
23715113
7.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group.

Ann Rheum Dis. 2003 Sep;62(9):817-24. Review.

8.

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.

Omair MA, Alnaqbi KA, Lee P.

Clin Rheumatol. 2012 Aug;31(8):1259-61. doi: 10.1007/s10067-012-2002-8. Epub 2012 May 27. Review.

PMID:
22644089
10.

Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.

Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI, Cherchiglia ML, Acurcio Fde A.

Rheumatol Int. 2013 Sep;33(9):2199-213. doi: 10.1007/s00296-013-2772-6. Epub 2013 May 18. Review.

PMID:
23686218
11.

A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

Santiago T, Santiago MG, Rovisco J, Duarte C, Malcata A, da Silva JA.

Clin Rheumatol. 2013 Dec;32(12):1819-22. doi: 10.1007/s10067-013-2361-9. Epub 2013 Aug 17. Review.

PMID:
23955767
12.

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

Armstrong N, Joore M, van Asselt T, Misso K, Manning N, Tomini F, Kleijnen J, Riemsma R.

Pharmacoeconomics. 2013 May;31(5):415-25. doi: 10.1007/s40273-013-0049-2. Review.

PMID:
23580355
13.

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network.

Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Review.

14.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Callhoff J, Sieper J, Weiß A, Zink A, Listing J.

Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9. Review.

PMID:
24718959
15.
16.

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

Ko JM, Gottlieb AB, Kerbleski JF.

J Dermatolog Treat. 2009;20(2):100-8. doi: 10.1080/09546630802441234. Review.

PMID:
18923992
17.

[Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].

Andreu JL, Otón T, Sanz J.

Reumatol Clin. 2011 Jan-Feb;7(1):51-5. doi: 10.1016/j.reuma.2009.03.007. Epub 2010 Apr 10. Review. Spanish.

19.

[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].

Wendling D, Claudepierre P, Lohse A, Toussirot E, Breban M.

Presse Med. 2003 Oct 4;32(32):1517-24. Review. French.

PMID:
14534471
20.

Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.

Zou JX, Braun J, Sieper J.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S34-7. Review.

PMID:
12463444

Supplemental Content

Support Center